COMMUNIQUÉS West-GlobeNewswire

The Ensign Group, Inc. Increases Quarterly Dividend to $0.0650 Per Share
19/12/2025
SAN JUAN CAPISTRANO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
19/12/2025
Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without [...]
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
19/12/2025
With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trials NEW YORK, Dec. 19, 2025 (GLOBE [...]
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
19/12/2025
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call today at 10:00 a.m. ET [...]
OKYO Pharma to Ring the Opening Bell at Nasdaq
19/12/2025
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular [...]
Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
19/12/2025
MSD declines to exercise option for EVX-B2 development Evaxion is now able to out-license EVX-B2 to another partner Evaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in [...]
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/12/2025
FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the [...]
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP)
19/12/2025
PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation [...]
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
19/12/2025
PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and [...]
Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone
19/12/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2025 – 7:00 AM CET Fagron accelerates global expansion with two strategic acquisitions and a key North American [...]
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire
19/12/2025
Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, [...]
IBA acquires ORA expanding its strategic leadership in Nuclear Medicine
19/12/2025
Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global [...]
DXS INTERNATIONAL PLC (AQSE: DXSP) Result of AGM
19/12/2025
19 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Result of DXS AGM 2025 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision [...]
Genenta Science Provides Update on CEO Ownership
19/12/2025
MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update [...]
Sai Life Sciences Releases Sustainability Report 2024–25
19/12/2025
HYDERABAD, India, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO) , today [...]
GUERBET: Nomination de M. François Convenant en tant que Senior Vice-Président Radiologie Interventionnelle et son entrée au Comité Exécutif
19/12/2025
Guerbet annonce la nomination de M. François Convenant en tant que Senior Vice-Président Radiologie Interventionnelle et son entrée au Comité Exécutif Villepinte, le 19 décembre 2025 : GUERBET (FR0000032526 GBT), acteur [...]
Guerbet: Appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee
19/12/2025
Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee Villepinte, December 19, 2025: GUERBET (FR0000032526 GBT), a [...]
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19/12/2025
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U . S . , if approved by the FDA, in the fourth quarter of 2026 , or earlier under certain circumstances [...]
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19/12/2025
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK [...]

Pages